Veytics Intelligence
2026-11-10 · NASDAQ

TransMedics: 3 Key Takeaways for Long-Term Investors

Key PointsTransMedics raised 2026 revenue guidance to $764 million to $774 million.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.

Register to read full article I already have an account Open original source: NASDAQ